CompletedPhase 2

Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor

China14 participantsStarted 2013-04

Plain-language summary

Temozolomide or dacarbazine-based chemotherapy combined with endostatin have efficacy in well-differentiated pancreatic neuroendocrine tumor

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. 18 years of age and older
✓. ECOG ≤2
✓. Pathologically confirmed locally advanced or metastatic well-differentiated pancreatic neuroendocrine tumor.
✓. Prior treatment with one-line chemotherapy is allowed, with the exception of prior treatment with temozolomide or dacarbazine or endostatin within the past 6 months
✓. Disease progressed during or after last therapy
✓. Minimum of 4 weeks since any major surgery, completion of radiation, or completion of all prior systemic anticancer therapy
✓. Disease progressed within the past 12 months。
✓. Patients must have at least one measurable site of disease according to RECIST1.1 criteria that has not been previously irradiated.

✕. Concurrent use of Octreotide or other drug that may have efficacy in neuroendocrine tumor.
✕. 2 or more lines of prior chemotherapy。
✕. Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study
✕. Uncontrolled infectious disease。
✕. Other malignancies within the past 5 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinoma of the skin
✕. Uncontrolled brain or leptomeningeal metastases
✕. Patients with known hypersensitivity to temozolomide or endostatin。
✕. Patient could not take tablets。

overall response rate

Timeframe: up to 12 months

NCT IDNCT01845675

SponsorPeking Union Medical College Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-11-30

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. 18 years of age and older
✓. ECOG ≤2
✓. Pathologically confirmed locally advanced or metastatic well-differentiated pancreatic neuroendocrine tumor.
✓. Prior treatment with one-line chemotherapy is allowed, with the exception of prior treatment with temozolomide or dacarbazine or endostatin within the past 6 months
✓. Disease progressed during or after last therapy
✓. Minimum of 4 weeks since any major surgery, completion of radiation, or completion of all prior systemic anticancer therapy
✓. Disease progressed within the past 12 months。
✓. Patients must have at least one measurable site of disease according to RECIST1.1 criteria that has not been previously irradiated.

✕. Concurrent use of Octreotide or other drug that may have efficacy in neuroendocrine tumor.
✕. 2 or more lines of prior chemotherapy。
✕. Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study
✕. Uncontrolled infectious disease。
✕. Other malignancies within the past 5 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinoma of the skin
✕. Uncontrolled brain or leptomeningeal metastases
✕. Patients with known hypersensitivity to temozolomide or endostatin。
✕. Patient could not take tablets。